Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $37.67 USD
Change Today -0.08 / -0.21%
Volume 36.0K
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

biospecifics technologies (BSTC) Snapshot

Open
$38.47
Previous Close
$37.75
Day High
$38.47
Day Low
$37.45
52 Week High
10/31/14 - $42.00
52 Week Low
04/30/14 - $22.23
Market Cap
254.0M
Average Volume 10 Days
23.0K
EPS TTM
$0.66
Shares Outstanding
6.7M
EX-Date
--
P/E TM
57.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOSPECIFICS TECHNOLOGIES (BSTC)

biospecifics technologies (BSTC) Related Bloomberg News

View More Bloomberg News

biospecifics technologies (BSTC) Related Businessweek News

No Related Businessweek News Found

biospecifics technologies (BSTC) Details

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX brand in Canada, Australia, Brazil, and Mexico, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.

5 Employees
Last Reported Date: 03/16/15
Founded in 1957

biospecifics technologies (BSTC) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

biospecifics technologies (BSTC) Key Developments

BioSpecifics Technologies Corp. Announces Appointment of Jennifer Chao and Jyrki Mattila to its Board of Directors

BioSpecifics Technologies Corp. announced the appointment of two new members to its Board of Directors, Ms. Jennifer Chao and Jyrki Mattila, M.D., Ph.D. Ms. Jennifer Chao is an Advisory Analyst at CoreStrategies Management, LLC. Previously, she served as Managing Director and Senior Analyst, Biotechnology at Deutsche Bank, Managing Director and Senior Analyst, Biotechnology at RBC Capital Markets, and Senior Analyst, Biotechnology at Leerink Swann. Dr. Jyrki Mattila has served as Chief Business Officer at iCeutica Inc. since October 2013.

BioSpecifics Technologies Corp. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 02:20 PM

BioSpecifics Technologies Corp. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 02:20 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Thomas L. Wegman, Chief Executive Officer, President, Principal Financial Officer, Principal Accounting Officer, Secretary, Director, President of ABC-Curacao, President of ABC-New York, Secretary of ABC-Curacao, Secretary of ABC-New York, Director - ABC-Curacao and Director of ABC-New York.

BioSpecifics Technologies Corp. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

BioSpecifics Technologies Corp. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. Net income of $1.9 million for the fourth quarter ended December 31, 2014, or $0.29 per basic share and $0.27 per share on a fully diluted basis, compared to net income of $1.7 million, or $0.27 per basic share and $0.25 per share on a fully diluted basis for the same period in 2013. Total revenue for the fourth quarter ended December 31, 2014 was $4.7 million, compared to $4.1 million for the same period in 2013. Operating income was $2.86 million against $2.57 million a year ago. EBIT was $2.87 million against $2.58 million a year ago. For the full year ended December 31, 2014, the company reported a net income of $4.6 million, or $0.72 per basic share and $0.66 per share on a fully diluted basis, compared to net income of $5.3 million, or $0.83 per basic share and $0.76 per share on a fully diluted basis for the same time period in 2013. Total revenue was $14.1 million, compared to $14.5 million for the same period in 2013. Operating income was $6.99 million against $7.94 million a year ago. EBIT was $7.032 million against $7.97 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSTC:US $37.67 USD -0.08

BSTC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BSTC.
View Industry Companies
 

Industry Analysis

BSTC

Industry Average

Valuation BSTC Industry Range
Price/Earnings 57.5x
Price/Sales 17.7x
Price/Book 8.4x
Price/Cash Flow 54.8x
TEV/Sales 16.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOSPECIFICS TECHNOLOGIES, please visit www.biospecifics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.